Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis by Martín, Andrea P. et al.
Administration of a Peptide Inhibitor of 4-Integrin
Inhibits the Development of Experimental
Autoimmune Uveitis
Andrea P. Martı´n,1,2,3 Luciana Vieira de Moraes,1,2 Carlos E. Tadokoro,1
Alessandra G. Commodaro,1 Enrique Urrets-Zavalia,4 Gabriel A. Rabinovich,5
Julio Urrets-Zavalia,4 Luiz V. Rizzo,1,6,7 and Horacio M. Serra3
PURPOSE. Recruitment of lymphocytes into the retina and to the
vitreous during the development of experimental autoimmune
uveitis (EAU) is governed by factors such as the state of acti-
vation of inflammatory cells and the repertoire of adhesion
molecules expressed by the local vascular endothelia. 4 Inte-
grins and their receptors play an important role during homing
of cells to the inflammatory site. In the present study, the effect
of 4-integrin inhibitor on the development of EAU was inves-
tigated.
METHODS. EAU was induced either by immunizing B10.RIII
mice with the 161-180 peptide or by adoptive transfer of
interphotoreceptor retinoid-binding protein (IRBP)–specific
uveitogenic T cells. Animals were treated with an active pep-
tide inhibitor (4-api) or a peptide control at different time
points after induction of disease. EAU was evaluated by histol-
ogy 21 to 49 days after immunization. Antigen-specific cell
proliferation was evaluated by thymidine incorporation. Cyto-
kine synthesis in culture supernatants and anti-IRBP-specific
serum IgG1 and IgG2a were evaluated by ELISA. Delayed-type
hypersensitivity was evaluated by ear challenge 2 days before
the termination of the experiment.
RESULTS. Treatment with 4-api had a significant ameliorating
effect on EAU. The anti-IRBP antibody response and cellular
proliferation were not affected by the treatment, whereas de-
layed-type hypersensitivity was significantly diminished. Cyto-
kine synthesis was not changed by treatment, except for a
decrease in IL-10 levels.
CONCLUSIONS. The results show that small-molecule inhibitors of
4-integrins can act therapeutically in EAU, possibly by inter-
fering with cell adhesion events involved in the development
of the disease. (Invest Ophthalmol Vis Sci. 2005;46:2056–2063)
DOI:10.1167/iovs.04-0418
Experimental autoimmune uveitis (EAU) is an organ-specific,T-cell-mediated disease that is characterized by inflamma-
tion and subsequent destruction of the neural retina and adja-
cent tissues. EAU can be induced in rodents and primates by
immunization with one of several retinal antigens. Disease can
also be induced by adoptive transfer of retinal antigen-specific
CD4 T cells in syngeneic rodents.1 The pathologic and clini-
cal courses of EAU in the mouse model closely resemble those
in human uveitis of putative autoimmune etiology.2,3 There-
fore, the study of immunologic mechanisms affecting EAU can
help in the understanding of human ocular autoimmunity as
well as other organ-specific, T-cell–mediated autoimmune dis-
eases.
In EAU, damage to the eye is caused by infiltrating lympho-
cytes, macrophages, and polymorphonuclear cells. Recruit-
ment of these cells is a fundamental step in the development of
the disease. The lymphocyte population that migrates to the
eye is constituted by both retinal antigen-specific lymphocytes
and nonspecific cells.4–6 In general, lymphocyte extravasation
is governed by a variety of factors, such as the state of cell
activation and the repertoire of adhesion molecules expressed
by the local vascular endothelia.7,8 Lymphocyte traffic into the
retina, however, is controlled not only by these factors but also
by the group of components that confer immune privilege to
the eye.9 One of the first steps in the pathogenesis of EAU is
the binding of leukocytes to the vascular endothelium of the
blood–retinal barrier (BRB). This initial interaction is followed
by diapedesis of the leukocytes and their subsequent migration
into the retina and the choroid’s parenchyma.10–12
T cells play a crucial role in the induction of EAU1,13 and in
later stages of the disease when Th1-type cells and macro-
phages invade the retina and destroy the photoreceptor cell
layer and the choroid, causing ocular damage.13,14 Even
though the role of the integrin family of adhesion molecules
has not been studied extensively in EAU, it has been demon-
strated in experimental allergic encephalomyelitis (EAE) that
the expression of very late antigen (VLA)-4 (41) is required
for encephalitogenic T-cell clones to enter the central nervous
system (CNS) and induce disease.15,16 Furthermore, treatment
with monoclonal antibodies (mAbs) against 4-integrins sup-
presses clinical signs and cell recruitment to the CNS in some
EAE models.17,18
The extensive distribution of adhesion molecules on the
endothelium of the vessels in the retina and iris in biopsy
specimens obtained from patients with uveitis and the contri-
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bution of integrins to lymphocyte binding to these vessels has
suggested that they play an important role in the development
of the disease.19,20 It has been suggested that lymphocyte
adhesion to the retinal vessels is dependent on CD29 expres-
sion (the common chain of 1-integrins), whereas expression
of CD11a/CD18 or CD49d is not as crucial.21 It has also been
shown that the expression of vascular cell adhesion molecule
(VCAM)-1 and lymphocyte function-associated antigen (LFA)-1
in the vascular endothelium of the iris from patients with
uveitis is increased, as well as the number of intercellular
adhesion molecule (ICAM)-1 and VLA-4-positive cells.19 B10.A
mice immunized with interphotoreceptor retinoid-binding pro-
tein (IRBP) have an increased expression of ICAM-1 in the eyes
before histologic evidence of inflammation. Monoclonal anti-
bodies against ICAM-1 and LFA-1 were effective in inhibiting
EAU in these animals.22 In addition, an in vitro study in a rat
model has confirmed that lymphocyte adhesion and transmi-
gration across monolayers of IFN--activated retinal pigmented
epithelial (RPE) cells are inhibited by mAbs against VLA-4 and
VCAM-1 in a rat model.23 Blood vessels in the retina also
express VCAM-1 during the development of EAU, which seems
to be involved in lymphocyte migration into the eye.20,23
VLA-4 and 47-integrins can interact with the CS-1 domain
of fibronectin (Fn) and VCAM-1.24,25 We and others have re-
ported that CS-1 Fn is expressed in the blood vessels under
different inflammatory conditions in which this molecule can
be involved in cell–cell interactions.25,26 Interactions of VLA-4
with both of these ligands—VCAM-1 and Fn—can be blocked
by peptides containing the CS-1 motif.27–29 Because these
peptides can interfere in the binding activity of VLA-4, the
inhibition of 4-mediated adhesion may be an attractive treat-
ment to prevent the development of EAU. Modified peptide
inhibitors have recently been used with chemical adaptations
that make them more suitable for clinical application30–32 and
in the treatment of different inflammatory diseases in experi-
mental models.27,33–36
In the present study, we investigated the role of an 4-
integrin inhibitor peptide, a CS-1 ligand mimetic, on the course
of actively induced EAU in B10.RIII mice.
MATERIALS AND METHODS
Animals
Six- to 8-week-old B10.RIII mice were obtained from our own animal
facilities at the University of Sa˜o Paulo. All animals were housed under
specific pathogen-free conditions and treated according to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
The animal care and use committee at the Institute of Biomedical
Sciences (University of Sa˜o Paulo) approved all the procedures used in
the study.
Antigen and Reagents
Peptide SGIPYIISYLHPGNTILHVD representing residues 161-180 of
IRBP was synthesized using Fmoc chemistry on a peptide synthesizer
(Pioneer, Applied Biosystems [ABI], Foster City, CA). Pertussis toxin
(PTX) and CFA were purchased from Sigma-Aldrich (St. Louis, MO).
The active 4-integrin inhibitor phenylacetyl-L-leucyl-L-aspartyl-L-pheny-
lalanyl-morpholineamide (4-api) and the scrambled version (inactive
control agent) were generated by Cytel Corp. (San Diego, CA). These
compounds were dissolved in sterile PBS (0.01 M; pH 7.4) at a con-
centration of 10 mg/mL and stored at 70°C before use.
Induction of EAU
Mice were immunized by a subcutaneous injections at the base of the
tail and neck with 50 g IRBP (161-180) emulsified in 0.2 mL complete
Freund’s adjuvant (CFA; vol/vol). At the same time, they were injected
intraperitoneally with 0.40 g PTX in 0.1 mL DMEM, as an additional
adjuvant. Alternatively, animals received intravenously 106 CD4 T
cells from a uveitogenic T-cell line described previously.37 Before
injection, the uveitogenic cells were stimulated in vitro with 30 g/mL
IRBP for 48 hours.
Anti-VLA-4 Treatment
Animals were injected intraperitoneally with 10 mg 4-api or an inac-
tive peptide control in some experiments, in 0.1 mL during the afferent
(days 2, 4, and 6) or efferent (days 14, 16, and 18) phase after
immunization (day 0). In some experiments, animals were treated on
days 14, 16, 18, 21, 25, 29, and 31 after immunization or only on days
21, 25, 29, and 31 after immunization. In these experiments, eyes were
enucleated 35 days after immunization. In adoptive transfer experi-
ments, animals were treated with the same dose of 4-api on days 1, 3,
5, 7, and 9 after transfer of uveitogenic T cells. In one set of experi-
ments, animals were killed 49 days after immunization.
Delayed-Type Hypersensitivity
Two days before the termination of an experiment, mice received 10
g of IRBP in 10 L intradermically in the left ear. The other ear was
injected with the same volume of PBS. Ear swelling was measured at
the termination of the experiment (48 hours later) with an electronic
micrometer. Delayed-type hypersensitivity (DTH) results are expressed
as antigen-specific swelling, calculated as the difference between the
thicknesses of the IRBP- and the PBS-injected ears.
Fundoscopy
Animals received a drop of phenylephrine 10% and tropicamide 1% in
each eye. Five minutes after administration of the mydriatic drug,
animals were anesthetized, and examination of the eye fundus was
performed with a stereoscope (MZ08; Leika, Heidelberg, Germany)
under 20 magnification. Mice were scored for uveitis according to
the criteria described in the next section.
Scoring of EAU
Eyes were collected and prepared for histologic evaluation at the end
of each experiment. The eyes were immersed for 1 hour in phosphate-
buffered glutaraldehyde 4%, transferred into phosphate-buffered form-
aldehyde 10% for 24 hours, and placed in ethanol 70% until processing.
Fixed and dehydrated tissue was embedded in paraffin wax, and 4- to
6-m sections were cut through the pupillary–optic nerve plane.
Sections were stained by hematoxylin and eosin. Presence or absence
of disease was evaluated in a double-blind fashion in six sections cut at
different levels in each eye. The severity of EAU was scored on a scale
of 0 (no disease) to 4 (maximum disease) in half-point increments,
according to lesion type, size, and number, by using a semiquantitative
system described previously.38,39 In brief, the minimal criterion to
score an eye as positive by histopathology was inflammatory cell
infiltration of the ciliary body, choroid, or retina (EAU grade 0.5).
Progressively higher grades were assigned for the presence of discrete
lesions in the tissue, such as vasculitis, granuloma formation, retinal
folding and/or detachment, and photoreceptor damage.
Lymphocyte Proliferation
Draining lymph nodes were collected and pooled within each group at
the end of each experiment (21 days after immunization). Triplicate
cultures of 5  105 cells/well were stimulated with 30 g/mL IRBP in
96-well flat-bottomed plates in DMEM containing 10% FCS and supple-
mented with 105 M 2-mercaptoethanol, 2 mM L-glutamine, 0.1 mM
nonessential amino acids, 50 g/mL gentamicin, 1 mM sodium pyru-
vate, and 20 mg/mL of -methyl-mannopyranoside, to quench any
residual concanavalin A remaining from the chromatography prepara-
tion of IRBP. The cell cultures were incubated for 96 hours and pulsed
with [3H]thymidine (0.5 Ci/well) during the last 18 hours of incuba-
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tion. The results are given as a stimulation index (SI), calculated as
follow, with CPM denoting counts per minute:
SI
CPM in stimulated cultures
CPM in cultures without stimulation
Determination of Cytokine Production in
Lymphocyte Cultures
Lymph node cells harvested on the day the animals were killed were
cultured at 106 cells/well and stimulated with 30 g/mL IRBP. Super-
natants were collected for cytokine analysis after 24 or 48 hours and
stored at 80°C until assayed. The levels of IFN- and IL-4, -5, -10, -12,
and -18 were evaluated by ELISA, using antibody pairs from BD-Pharm-
ingen (La Jolla, CA) or ELISA kits from Pierce Biotechnology, Inc.
(Rockford, IL). All materials were used according to the manufacturers’
instructions.
Assay for IRBP-Specific Antibodies
Anti-IRBP IgG1 and IgG2a isotype levels were determined by ELISA, as
previously described.40 Briefly, 96-well microtiter plates (Corning
Costar, Corning, NY) were coated with IRBP at 1 g/mL for 4 hours at
room temperature (RT), blocked with PBS-BSA 1% (Sigma-Aldrich) for
1 hour at RT, washed twice with PBS and incubated for 2 hours with
serum samples. Plates were washed again and developed with horse-
radish-peroxidase–conjugated rat anti-mouse IgG1 or rat anti-mouse
IgG2a (Southern Biotechnology Associates, Birmingham, AL) for 1 hour
at RT. Plates were washed and incubated with the substrate (0.1 M
citric acid, 0.2 M Na2HPO4 [pH 5.0], 20 L H2O2, and 20 mg o-
phenylenediamine). The concentration of anti-IRBP Ab was estimated
using standards curves constructed by coating wells with anti-Ig Ab
against the appropriate isotype and adding polyclonal Ig standards of
the corresponding isotype.
Statistical Analysis
Results are representative of two or three independent experiments.
Statistical analysis of EAU scores was performed using the Snedecor-
Cochran test for linear trends in proportion.41 Each mouse (average of
both eyes) was treated as one statistical event. Results were considered
significant when P  0.05.
RESULTS
Effect of an 4-Integrin Inhibitor on the
Development of IRBP-Induced EAU
Disease was induced in B10.RIII mice as described in the
Materials and Methods section. Animals were treated intraperi-
toneally with either 4-api or the control peptide during the
afferent (days 2, 4, and 6) or efferent phases of the disease
(days 14, 16, and 18). Mice from the control group became
clinically ill and showed moderate to severe signs of EAU in
histopathologic examination on day 21. Grading of the eyes
showed that treatment with 4-api during the efferent phase
significantly ameliorated the severity of the disease (mean EAU
score of 1.05; P  0.042 when compared with the control
animals; Fig. 1A). By contrast, mice from the group treated
with 4-api during the afferent phase of disease exhibited EAU
of a grade similar to that in the control animals (scores 2.0 and
2.5, respectively). Histopathology of the eyes of the control
group on day 21 showed retinal disorganization; photorecep-
tor destruction; inflammatory cells in the vitreous, uvea, and
retina; retinal vasculitis; and granuloma formation (Fig. 1B,
right). In contrast, mice treated with 4-api during the efferent
phase showed a normal retinal architecture (Fig. 1B, left).
When only the animals that had EAU were analyzed by fundos-
copy, disease onset was not shown to be significantly affected
by treatment with 4-api. Disease onset in the control group
was between days 8 and 13. In mice treated in the afferent
phase, it was between days 9 and 14; and in mice treated in the
efferent phase it was between days 10 and 14. The effect of
4-api during the efferent phase of disease was confirmed by
its effectiveness in preventing the development of EAU in mice
that received uveitogenic T cells intravenously (Fig. 2). Animals
received 106 uveitogenic T cells. Eyes were harvested 14 days
after immunization, which corresponds to the peak of disease
in this adoptive transfer model. Treatment with the peptide
resulted in amelioration of disease whether animals received it
immediately after adoptive transfer (days 1, 3, and 5), or later
(days 5, 7, and 9). These results suggest that the effect of the
inhibitor is, at least in part, due to a blockade in the migration
of activated T cells to the retina.
To test whether treatment during the efferent phase would
simply delay the onset of disease, we observed animals immu-
nized with a uveitogenic dose of IRBP for 35 days after immu-
nization. Results are presented in Figure 3. As can be seen,
treatment with 4-api in the efferent phase of disease was still
effective in protecting against disease during this period,
which suggests that treatment in the efferent phase does not
simply delay the onset of disease, although continuous treat-
ment is necessary to achieve the maximal effect. It is interest-
ing to note that if treatment with 4-api started after the
disease peaked (days 21–31, four-dose treatment) it was less
effective than prolonged treatment from the efferent phase
until day 31 (days 14–31, seven-dose treatment). Since the
FIGURE 1. The 4-integrin inhibitor suppresses the clinical signs of
actively induced EAU. B10.RIII mice were immunized with 50 g of
IRBP (161-180) on day 0 and treated with 10 mg intraperitoneal 4-api
or a peptide control on days 2, 4, and 6 (afferent phase) or days 14, 16,
and 18 (efferent phase). Control animals received 10 mg of an inactive
peptide control on days 2, 4, 6, 14, 16, and 18. Eyes were collected for
histopathology 21 days after immunization. (A) EAU scores were as-
signed on a scale from 0 to 4 according to the extent of inflammation
and tissue damage. Each point represents one mouse (average of both
eyes). Data are a compilation of results in two independent experi-
ments. Mice treated with 4-api ameliorated the ocular inflammatory
response (p  0.05). Horizontal axis: Data represent the mean sever-
ity of the disease. (B) Histopathology of EAU showing a picture rep-
resentative of each group of animals. Right: control mouse. Note the
loss of the photoreceptor layer, retinal detachment (R), inflammatory
cells (thin arrows) in the vitreous (V) and subretinal space, and retinal
granuloma formation (thick arrow) Left: mouse treated with 4-api.
Note the well-preserved retinal architecture. Magnifications: (right)
400; (left) 100.
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necessity for continuous treatment to maintain protection
could be related to the development of tolerance to the inhib-
itor, we decided to treat mice in the afferent and efferent
phases as described previously, either with 4-api or with
control peptide and evaluated them for EAU grade 49 days after
immunization. Results indicated that mice treated with the
control peptide in either phase of EAU development displayed
significant disease scores (2.5  1, with 100% incidence of
disease, 6/6 mice). Mice treated with 4-api in the afferent
phase of disease had slightly lower disease grades (2.0  0.5
with 70% incidence, 7/10 mice), and animals treated in the
efferent phase showed even lower grades (1.5  0.5 with 70%
incidence, 7/10 mice). Compared with disease grades at day
21, the data suggest that continuous treatment is necessary to
obtain the maximal effect of the VLA-4 inhibitor, although
short-term treatment during the efferent phase has some long-
term protective effects.
Effect of 4-Api on DTH and the Proliferative
Response to IRBP
Because treatment with 4-api during the efferent phase of the
disease resulted in a blockade of EAU development, we next
investigated the effects of the 4-api on the DTH response to
IRBP and the specific proliferative response. Ear challenge for
DTH was performed 19 days after immunization in mice
treated with 4-api and in control subjects in the efferent
phase of the disease. Swelling of the ear was significantly less
prominent in the 4-api-treated mice, with a fourfold reduction
in the DTH response (P  0.05) when compared with the
control group (Fig. 4A). In contrast, the proliferative response
to IRBP on day 21 after immunization in 4-api-treated mice
was unchanged compared with the control animals (Fig. 4B).
Because we have not tested the DTH response in control mice
treated only on days 18 and 20, it is possible that the exuberant
FIGURE 2. The 4-integrin inhibitor peptide suppressed EAU induced
by adoptive transfer. B10.RIII mice received 106 cells from a uveito-
genic T-cell line on day 0 or not and were treated with 10 mg 4-api
intraperitoneally on days 1, 3, and 5 (eight mice) or days 5, 7, and 9
(seven mice). Eyes were enucleated and analyzed for EAU by histology
14 days after adoptive transfer. EAU scores were determined as de-
scribed in Materials and Methods. Data represent the mean disease
score; error bars are the standard deviation. Mice treated with 4-api in
both regimens showed an amelioration of the ocular inflammatory
response (P  0.05).
FIGURE 3. Continuous treatment with the VLA-4 peptide inhibitor
was necessary for maintenance of the protective effect. B10.RIII mice
(five in each group) were immunized with 50 g of IRBP (161-180) on
day 0 and treated with 10 mg 4-api intraperitoneally on the afferent
phase (aff) or efferent (eff) phase as described in Materials and Meth-
ods. In addition, animals were treated with four doses of 4-api (days
21, 25, 29, and 31 after immunization; eight mice) or with seven doses
(days 14, 16, 18, 21, 25, 29, and 31 after immunization; seven mice).
Eyes were collected for histopathology 35 days after immunization,
and the EAU scores determined. Data represent the mean disease
score; error bars: standard deviation. Mice treated with 4-api in all
regimens showed an amelioration of the ocular inflammatory response
(P  0.05), except for mice treated on the afferent phase.
FIGURE 4. 4-Integrin inhibitor reduces DTH, but has no effect on the
proliferative response to IRBP. (A) Immunized B10.RIII mice treated or
not treated with 4-integrin inhibitor in the efferent phase were tested
for DTH to IRBP by intradermal injections of 10 g IRBP in one ear and
PBS in the other ear 2 days before the termination of the experiment.
After 48 hours, ear swelling was measured. DTH response was reduced
in mice treated with 4-api (P  0.05). DTH results are expressed as
antigen-specific swelling and calculated as the difference between the
thickness of the IRBP- and the PBS-injected ears. Results are expressed
as mean  SD. (B) The lymphoproliferative response to IRBP was
determined 21 days after immunization. Draining lymph node cells
were collected and stimulated in vitro with 30 g/mL IRBP. Cultures
were incubated for 96 hours and pulsed with [3H]thymidine for the last
18 hours. Proliferation is represented as a stimulation index  SD.
Results are expressed as the mean  SD and represent the average of
15 mice in the treated group and 12 mice in the control group, in three
separate experiments (*P  0.05).
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effect observed was at least partly caused by an inhibition of
the skin response itself.
Effect of Blockade of 4-Integrin Interactions
with Its Ligands on the Th2 Shift
It has been shown that a shift to a Th2 cytokine profile can
result in a decrease in incidence and severity of EAU, without
a significant effect in the lymphoproliferative response to ret-
inal antigens.42,43 Draining lymph node cells from 4-api-
treated or control mice were harvested 21 days after immuni-
zation and assayed for cytokine levels in supernatants from
IRBP-stimulated cells. Although treatment with 4-api had no
effect on the production of IFN-, increased amounts of IL-18
were observed (Fig. 5). In all experiments both IL-4 and -5
levels were at or below the detection limit (data not shown).
Moreover, the production of IL-10 was decreased when com-
pared with that in the control group, and no differences were
observed in IL-12 secretion between the groups (Fig. 5). Our
data thus indicate that amelioration of EAU induced by treat-
ment with 4-api is not associated with a shift in cytokine
profile. Treatment in the afferent phase did not influence
cytokine synthesis (data not shown). However, because of the
experimental system used, we cannot rule out that the changes
observed are fleeting; and because cytokine measurements
were performed more than 2 weeks after the last administra-
tion of the inhibitor, these may not have persisted long enough
to be noticed at the time point of the measurements.
Nevertheless, it is still possible that a minor or transient
change in the cytokine profile would not necessarily translate
into in vitro cytokine synthesis. We have shown that antigen-
specific antibody isotypes are good indicators of the cytokines
secreted during an immune response.40,43 Because IFN- and
IL-4 promote immunoglobulin (Ig) isotype switching to IgG2a
and IgG1, the relative amounts of these isotypes in mice sera
may reflect the balance between Th1 and Th2 responses. Our
results show that treatment with 4-api does not affect anti-
IRBP IgG2a antibodies, although anti-IRBP IgG1 was decreased
in the 4-api-treated animals compared with the control (Fig.
6), supporting the in vitro data on cytokine production after
this treatment. Taken together, our results suggest that VLA-4
blockade does not inhibit EAU by either changing the cytokine
profile of the retinal antigen-specific T cells or by silencing
them, but probably by blocking their recruitment to the in-
flammatory site.
DISCUSSION
The murine model of EAU was established several years ago39
and is thought to be a representative model for the study of
therapeutic approaches to human posterior uveitis. Studies
of genetic susceptibility and resistance to EAU,44 identification
of uveitogenic epitopes,38 and induction of tolerance to
EAU45–48 have been successfully performed in this model.
During EAU, immune cells infiltrate the parenchyma of the
eye and exert their destructive effects on the retina and cho-
roid. The process of cell recruitment to the eye involves a
series of cell-to-cell interactions, in both the vasculature and
ocular tissues. Although the requirement for 4-integrins in
cell recruitment to the retina has been well established,49–51
the precise role of these receptors at different steps of this
process has not been clearly defined. In the present study, we
show that treatment with the modified peptide 4-api reduces
the severity of clinical signs of EAU, as well as and cell recruit-
ment into the eye.
Although treatment with 4-api was effective in decreasing
the signs of EAU, it is noteworthy that it did not significantly
change the cytokine balance toward a Th2 profile, a character-
istic commonly seen on remission in the evolution of this
disease. It is also notable that production of IL-18 was increased
in the 4-api-treated group compared with the control mice.
Moreover, mice treated with the inhibitor at the afferent phase
showed enhanced levels of this cytokine in supernatants of
IRBP-specific lymph node cell cultures (data not shown). IL-18
is secreted by activated macrophages and dendritic cells and
acts synergistically with IL-12 to induce IFN- secretion by T
cells52 or NK cells.53 IL-18 has been also shown to upregulate
the expression of ICAM-1 and VCAM-1 on endothelial cells and
synovial fibroblasts from patients with rheumatoid arthritis.54
In our model, the overproduction of IL-18 in 4-api-treated
treated mice gave rise to two possibilities. The first suggests
that macrophages that have been activated after immunization
and migrated to the lymph nodes before treatment with VLA-4
inhibitor are the main source of IL-18. Because these cells are
trapped in this organ, it seems reasonable to assume that the
FIGURE 6. Anti-IRBP IgG1- and IgG2a/c-specific isotypes in B10.RIII
mice treated or not treated with an 4 peptide inhibitor at the efferent
phase. Immunoglobulins bound to IRBP-coated plates were quantified
by isotype-specific ELISA. Mice treated with 4-api showed decreased
production of anti-IRBP IgG1 as compared to the control (P  0.05).
Results are expressed as the mean  SD and are representative of 15
animals in the treated group and 10 animals in the control group.
FIGURE 5. Antigen-specific cytokine production in lymph node cells
from B10.RIII mice treated or not treated with an 4 peptide inhibitor
at the efferent phase. Draining lymph node cells were collected 21
days after immunization, pooled within each group, and stimulated
with 30 g/mL IRBP for 24 or 48 hours. Supernatants were harvested
and assayed by capture ELISA in triplicate. Mice treated with 4-api
showed decreased levels of IL-10 and increased production of IL-18 (P
 0.05). Results are expressed as the mean  SD and are representa-
tive of 15 animals in the treated group and 10 animals in the control
group.
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secretion of IL-18 is enhanced because of the increasing num-
ber of accumulating activated cells in these mice compared
with that in the control animals. Another possible explanation
is that the increased production of IL-18 enhances the expres-
sion of VCAM-1 on endothelial cells as a mechanism of positive
regulation because of the lack of interaction of these molecules
with VLA-4. One would expect that increased levels of IL-18
would be reflected by an enhanced secretion of IFN-. Because
there were no differences in IL-12 production between both
groups, one may hypothesize that IL-18 alone would not be
sufficient to enhance the production of IFN-. Another possi-
bility is that IFN- has reached its saturation levels and there-
fore maintained its production pattern.
Investigation of the production of anti-IRBP IgG1 and IgG2a
isotypes as markers of T2- and T1-type cytokines, respectively,
reinforces the notion that treatment with the VLA-4 inhibitor
did not induce a shift toward a Th2 profile, since the levels of
IgG1 were even lower when compared with those in control
animals. Canella et al.55 showed that in EAE, treatment with
another peptide inhibitor of VLA-4 results in amelioration of
the disease if the peptide is administered in the acute phase of
the disease. This phenomenon is due to changes in the proin-
flammatory cytokine profile as a consequence of an increase in
Th2 cytokines. Of note, their animals did not exhibit EAE, even
after cessation of the treatment. In our model, treatment with
an 4-integrin-blocking peptide was effective in the suppres-
sion of uveitis when used in the efferent phase of the disease,
which is characterized by inflammatory infiltrates in the eye of
activated cells. We observed suppression of the disease 21 days
after immunization, and our results strongly suggest that ame-
lioration of uveitis is dependent on the frequency of the ad-
ministration of the peptide. Furthermore, in our model we did
not see any changes in the cytokine pattern, which showed no
skewing toward the Th2 profile. Therefore, it is plausible to
assume that, different from the results obtained in EAE, the
administration of this peptide does not affect the expansion of
autoreactive cells and therefore does not interfere with the
pool of cells potentially capable of migrating to the eye.
VLA-4 is a known cell adhesion molecule, adhering to lym-
phocytes, that interacts with VCAM-1 and can induce activa-
tion and proliferation.32,56 Blockade of VLA-4 by small-mole-
cule inhibitors could interfere with this process, as it has been
shown in human T lymphocytes.57,58 Indeed, earlier studies
have indicated that blockade of T-cell activation suppresses the
clinical signs of EAU.59,60
The 4-integrin-blocking peptide was also efficient in sup-
pressing the development of EAU in the adoptive transfer
model. Decreasing disease grades were significant in treated
animals. In this model, the migration of uveitogenic T lympho-
cytes across the endothelium of the BRB occurred in a rela-
tively short time span, without the continuous induction of
uveitogenic T cells by the prolonged presence of antigen as in
actively induced EAU. This finding indicates that 4 integrins
are indeed essential in the recruitment of lymphocytes into the
eye, as suggested previously,22 and that blockade of integrin-
ligand interactions may be effective in preventing the entry of
uveitogenic cells.
In our model, inhibition of leukocyte migration by treat-
ment with anti-VLA-4 was also demonstrated by suppressed
DTH reaction in these animals. Previous reports have shown
that DTH responses to IRBP in C57BL/6 immunized mice are
characterized by the presence of a mononuclear cell infil-
trate.60 Although we have not evaluated the cell profile that
migrated to the lesions in control mice, minimal DTH re-
sponses in 4-api-treated mice may be a consequence of mi-
gration of cells that interact with the endothelia by adhesion
molecules different from VLA-4. Moreover, the proliferative
response to IRBP was not affected in anti-VLA-4-treated mice,
which strongly suggests that suppression of the clinical signs of
EAU in our study was mainly associated with the inhibition of
cell migration rather than a suppression of the immune re-
sponse to the specific antigen.
The precise nature of the 4-integrin ligand blocked by the
inhibitory peptide is not completely clear. VCAM-1 expression
in the eye was only observed on blood vessels adjacent to
histopathological lesions and in RPE cells in patients with
uveitis. VCAM-1 was upregulated after incubation with TNF-,
IFN-, and IL-1, indicating that this molecule is not constitu-
tively expressed at the cell surface.58 The other known 4-
ligand is the CS1 domain found in alternatively spliced forms of
Fn. Although there are no data about this ligand in the eye,
increased Fn expression has been found in the retinal vessels of
S-antigen-induced uveitis 1 to 2 days before the histologic and
clinical onset of EAU.61 Fn expression has also been observed
in the vascular basement membrane of the iris and in the
retinal vascular basement membrane in EAU in rats.61,62
In addition, a weak positivity for the CS1 domain has been
observed in blood vessels of CNS tissue during EAE, whereas
abundant expression has been observed on astrocytes in both
naı¨ve and EAE animals. Van der Laan et al.26 postulated that the
CS1-ligand motif expressed by astrocytes functions as a ligand
for VLA-4-positive leukocytes, as confirmed by in vitro experi-
ments in which the interaction between primary rat lympho-
cytes and astrocytes was substantially blocked by an 4 inhib-
itory peptide. The lack of cellular infiltrates in transferred EAE
in animals treated with 4-api may be caused by the lack of
adherence of transferred T cells to the astrocyte CS1 domain,
rather than from the lack of binding to VCAM-1.
In summary, in the current study, blockade of 4 integrins
had a beneficial effect on actively induced EAU. The recruit-
ment of T cells may involve interactions with VCAM-1 and CS-1
Fn. Furthermore, the use of 4 inhibitors may contribute as an
alternative therapeutic approach in the control autoimmune
ocular diseases.
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